MOLN vs. CLLS, DBVT, OMGA, AGEN, ZURA, VXRT, KPTI, BCAB, INMB, and VCXB
Should you be buying Molecular Partners stock or one of its competitors? The main competitors of Molecular Partners include Cellectis (CLLS), DBV Technologies (DBVT), Omega Therapeutics (OMGA), Agenus (AGEN), Zura Bio (ZURA), Vaxart (VXRT), Karyopharm Therapeutics (KPTI), BioAtla (BCAB), INmune Bio (INMB), and 10X Capital Venture Acquisition Corp. III (VCXB). These companies are all part of the "medical" sector.
Cellectis (NASDAQ:CLLS) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, community ranking, institutional ownership, earnings, analyst recommendations, valuation and dividends.
Molecular Partners has lower revenue, but higher earnings than Cellectis. Molecular Partners is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.
63.9% of Cellectis shares are held by institutional investors. Comparatively, 26.6% of Molecular Partners shares are held by institutional investors. 16.4% of Cellectis shares are held by insiders. Comparatively, 5.9% of Molecular Partners shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Cellectis has a net margin of -346.65% compared to Cellectis' net margin of -885.11%. Cellectis' return on equity of -31.10% beat Molecular Partners' return on equity.
Cellectis currently has a consensus price target of $8.50, indicating a potential upside of 240.00%. Molecular Partners has a consensus price target of $4.50, indicating a potential upside of 15.98%. Given Molecular Partners' stronger consensus rating and higher probable upside, equities analysts plainly believe Cellectis is more favorable than Molecular Partners.
Cellectis received 393 more outperform votes than Molecular Partners when rated by MarketBeat users. Likewise, 68.47% of users gave Cellectis an outperform vote while only 44.00% of users gave Molecular Partners an outperform vote.
Cellectis has a beta of 3.12, indicating that its share price is 212% more volatile than the S&P 500. Comparatively, Molecular Partners has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500.
In the previous week, Cellectis had 1 more articles in the media than Molecular Partners. MarketBeat recorded 2 mentions for Cellectis and 1 mentions for Molecular Partners. Cellectis' average media sentiment score of 0.25 beat Molecular Partners' score of 0.00 indicating that Molecular Partners is being referred to more favorably in the news media.
Summary
Cellectis beats Molecular Partners on 13 of the 18 factors compared between the two stocks.
Get Molecular Partners News Delivered to You Automatically
Sign up to receive the latest news and ratings for MOLN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MOLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Molecular Partners Competitors List
Related Companies and Tools
